

## Derivation and application of pluripotent stem cells for regenerative medicine

Jiaqiang Wang & Qi Zhou\*

State Key Laboratory of Stem cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China

Received March 30, 2016; accepted April 20, 2016

Pluripotent stem cells (PSCs) are cells that can differentiate into any type of cells in the body, therefore have valuable promise in regenerative medicine of cell replacement therapies and tissue/organ engineering. PSCs can be derived either from early embryos or directly from somatic cells by epigenetic reprogramming that result in customized cells from patients. Here we summarize the methods of deriving PSCs, the various types of PSCs generated with different status, and their versatile applications in both clinical and embryonic development studies. We also discuss an intriguing potential application of PSCs in constructing tissues/organs in large animals by interspecies chimerism. All these emerging findings are likely to contribute to the breakthroughs in biological research and the prosperous prospects of regenerative medicine.

**pluripotent stem cells, regenerative medicine, reprogramming, interspecies chimerism**

**Citation:** Wang, J., and Zhou, Q. (2016). Derivation and application of pluripotent stem cells for regenerative medicine. *Sci China Life Sci* 59, 576–583. doi: 10.1007/s11427-016-5066-x

### INTRODUCTION

The life cycle of an organism during development from a zygote to an adult is programmed with gradual loss of differentiation potency at cell level. Regenerative therapy can be achieved by replacing, engineering or regenerating damaged cells, tissues or organs to restore normal function, and holds great promise to cure some untreatable diseases such as spinal cord injury. It is believed that regenerative medicine will play an increasingly important role in medical revolution in the coming decades.

Pluripotent stem cells (PSCs) are the most important seed cells for regenerative medicine due to their unlimited self-renewal *in vitro* and differentiation capacity to form any type of cells *in vivo*. PSCs of different status can be isolated and established at different stages of an embryo or

from different tissues of an adult. Apparently, these stem cells have problems of immunological rejection and limited resource. The reversion of a cell into a state with a different gene expression profile (not always with increased potency) is called reprogramming. Reprogramming could generate patient-specific stem cells, making a great prospect for regenerative medicine. Nuclear transfer and overexpression of transcription factors, which includes both transdifferentiation and induced pluripotent stem cell (iPSC) technology, are recognized reprogramming methods.

Establishing animal disease/therapeutic models and animals with “organ niche” (Rashid et al., 2014) is another concept for regenerative medicine. With the development of functional genomic research and genome-editing technology, many disease models are generated. However, few of them can currently be applied in clinical study. Also, *in vivo* generation of human organs from donor stem cells in a xenogenic environment with “developmental compensation” or via 3D bio-printing is still a tough task.

\*Corresponding author (email: zhouqi@ioz.ac.cn)

## PLURIPOTENT STEM CELLS: HIGHER PLURIPOTENCY AND CLOSER TO HUMAN

Embryonic stem cells (ESCs) with highest pluripotency are good for cell-replacement therapies and for *in vitro* generation of organs, thus holding promise in treating degenerative disorders such as Parkinson's disease, Alzheimer's disease, and diabetes. Since the first successful derivations of mouse ESCs were reported in 1981 (Evans and Kaufman, 1981; Martin, 1981), ESCs have been successfully established in many species, including human (Thomson et al., 1998), monkey (Li et al., 2005a; Thomson et al., 1996), rat (Germana, 2011; Iannaccone et al., 1994; Li et al., 2012a), and rabbit (Wang et al., 2007, 2008), and a lot of efforts have been put into improving pluripotency of human ESCs (Gu et al., 2012; Hanna et al., 2010). Since the use of human ESCs for research and therapy must be with deliberation, the international consensus guidance for banking and supply of human ESCs for research purposes (International Stem Cell Banking, 2009) and the points to consider in the development of seed stocks of pluripotent stem cells for clinical applications have been enacted (Andrews et al., 2015).

For regenerative medicine, PSCs with higher pluripotency and lower immunological rejection are always needed. Tetraploid embryo complementation represents the golden standard of demonstration of the highest pluripotency of stem cells. However, only mouse ESCs and iPSCs (Zhao et al., 2009) have been demonstrated to have such developmental potency. For clinic application, transplantable neural progenitor cells from rat ESCs (Herson et al., 2003) and rhesus monkey ESCs (Chen et al., 2009; Li et al., 2005) were established, and the efficacy of neural progenitor-based transplantation therapy in the nonhuman primate was evaluated (Chen et al., 2009; Li et al., 2005). In addition, cynomolgus monkey ESCs with higher pluripotency with which monkey chimeric fetuses were generated have been obtained (Shuai et al., 2015). Human parthenogenetic ESCs (Hao et al., 2009; Shuai et al., 2015) and homozygous human androgenetic ESCs (Ding et al., 2015) were derived, providing important tools for future therapeutic use in a clinical setting.

## REPROGRAMMING: SOURCE OF PATIENT-SPECIFIC STEM CELLS

Reprogramming could generate patient-specific stem cells, so it may play a potentially important role in translating stem cells from basic research to clinical application.

### Nuclear transfer

The original design of nuclear transfer (NT) experiment was established by Briggs and King in 1952, by injecting a nucleus of a ruptured cell into an enucleated unfertilized xenopus egg (Briggs and King, 1952). The first successful

nuclear transfer experiment was accomplished by Gurdon and colleagues in 1958, with developing into adult xenopus (Gurdon et al., 1958). Chinese scientist Dizhou Tong generated the first cloned *Carassius auratus* in 1963, and performed the first interspecies nuclear transfer cloning between *Carassius auratus* and *Rhodeus sinensis* in 1973.

In 1997, Wilmut reported the birth of the first cloned mammal "Dolly" the sheep (Wilmut et al., 1997). Thereafter, mouse (Wakayama et al., 1998), cow (Cibelli et al., 1998; Kato et al., 1998), goat (Baguisi et al., 1999), pig (Betthausen et al., 2000; Onishi et al., 2000; Polejaeva et al., 2000), cat (Shin et al., 2002), rabbit (Chesne et al., 2002), mule (Woods et al., 2003), horse (Galli et al., 2003), rat (Zhou et al., 2003), dog (Lee et al., 2005), ferret (Li et al., 2006), and camel (Wani et al., 2010) were successively cloned. In 2006, cloned rhesus monkey blastocysts were generated, yet no cloned monkey have been produced so far (Zhou et al., 2006). In 2004, Hwang established the first nuclear transfer ESCs (ntESCs) (Hwang et al., 2004), being regarded as a milestone for therapeutic cloning. In addition, human oocyte morphology classification (Yu et al., 2009) and therapeutic cloning by xenotransplanted oocytes (Riaz et al., 2011) were also tried. Recently, fertile offspring from *Kit<sup>w</sup>/Kit<sup>wv</sup>* infertile male mice was generated through *in vivo* differentiation of gene corrected ntESCs (Yuan et al., 2015), and spermatid-like cells from mouse ESCs *in vitro* gametogenesis (Zhou et al., 2016) were derived, exploring new paths to rescue male infertility caused by genetic mutations (Yuan et al., 2015).

The reprogramming efficiency of nuclear transfer is very low, so lots of efforts have been made to improve the efficiency. The abnormal development of nuclear transfer embryos is always associated with defects in epigenetic reprogramming (Dean et al., 2001; Kang et al., 2001; Ohgane et al., 2001; Yamazaki et al., 2006). Treatment with histone demethylase inhibitor can increase the reprogramming efficiency (Bui et al., 2010; Dai et al., 2010; Kishigami et al., 2006; Song et al., 2014). Besides, modified culture methods showed that *in vitro* culture environment plays an important role in nuclear transfer reprogramming (Dai et al., 2009). It was also reported that some of the placental abnormality of nuclear transfer embryos can be blamed on the abnormal expression of some genes, such as *HSPC117* (Wang et al., 2010). Furthermore, protein profile of the mouse metaphase-II oocyte was analyzed, which might be valuable in revealing potential mechanisms of epigenetic reprogramming in nuclear transfer (Ma et al., 2008).

### Overexpression of transcription factors

As early as in 1987, Davis achieved transdifferentiation of fibroblasts into myocytes via overexpression of MyoD, and it was an innovative progress (Davis et al., 1987). Similarly, overexpression of *C/EBP $\alpha$*  can change pre-T cells (Laiosia et al., 2006) or pre-B cells (Xie et al., 2004) into macrophagocytes, as pancreatic exocrine acinar cells into liver

cells (Shen et al., 2000). In 2010, Shinya Yamanaka induced mouse fibroblast transdifferentiating into functional neural cells by overexpression of 19 neural-specific transcription factors. In 2012, successful transdifferentiation of Sertoli cells, one type of testis sustentacular cells, into neural stem cells was reported, and the obtained neural stem cells could survive and generate synapses following transplantation into the dentate gyrus. The work has important implications for regenerative medicine (Sheng et al., 2012a, b). In 2008, *in vivo* transdifferentiation of pancreatic acinar cells into pancreas islet  $\beta$  cells with normal insulin secretory function was accomplished by adenovirus-introduced overexpression of three transcription factors (Zhou et al., 2008).

In 2006, Takahashi and Yamanaka induced mouse fibroblasts into ESCs-like cells via overexpression of Oct4, Sox2, Klf4, and c-Myc (OSKM) (Takahashi and Yamanaka, 2006), the cells were named induced pluripotent stem cells (iPSCs). This shed light on regenerative medicine field. The generation of all-iPSCs-mouse “Xiaoxiao” with the method of tetraploid embryo complementation (Zhao et al., 2009, 2010a, b, c), and the verification of iPSCs’ capability to generate offspring through nuclear transfer (Zhou et al., 2010), paved the way for iPSCs to be used in regenerative medicine. Notably, however, mice generated from tetraploid complementation competent iPS cells show similar developmental features as those from ES cells but are prone to tumorigenesis (Tong et al., 2011), indicating that more efforts need to be made before iPSCs to be translated from basic research to clinical application.

Pig iPSCs attract a wide attention because pig is an important animal model for *in vitro* generation of human organ and there lacks pig ESCs. It was reported that mouse ESCs-like pig iPSCs were produced efficiently and they processed good cell viability and proliferation capability (Gu et al., 2014), although pig iPSCs with chimaeric ability have yet to be obtained.

Exogenous four transcription factor-coding genes in iPSC technology are the barrier for its application. In 2011, Anokye-Danso obtained OSKM-free iPSCs by transfecting miR-302/367 into fibroblasts (Anokye-Danso et al., 2011). Some other research groups used proteins generated from OSKM genes to induce iPSCs, and obtained satisfying results (Cho et al., 2010; Kim et al., 2009; Lee et al., 2012; Zhou et al., 2009). Furthermore, a chemical reprogramming system without gene-editing (Hou et al., 2013; Zhao et al., 2015) have also been developed.

Enhancing the efficiency of iPSCs reprogramming is important for their application. Adding active small molecules that are associated with epigenetic modification, such as VPA (Huangfu et al., 2008), DNA methylase inhibitors (Huangfu et al., 2008; Mikkelsen et al., 2008), histone methylase inhibitors (Shi et al., 2008), histone deacetylase inhibitor (Hai et al., 2011), protein arginine methyltransferase inhibitor (Yuan et al., 2011), or vitamin C (Esteban et al., 2010), has been reported to be able to increase the iPSCs

reprogramming efficiency. Similar to nuclear transfer, some maternal factors, such as TH2A and TH2B (Shinagawa et al., 2014), can promote iPSCs reprogramming. Also, the activity of endogenous retrovirus HERVH was shown to have connection with pluripotency of human iPSCs (Ohnuki et al., 2014). Notably, that the maternal unmethylated Dlk1-Dio3 region would turn methylation during iPSC reprogramming, which may be caused by disorder of c-Myc (Li et al., 2011) and/or Gtl2 (Das et al., 2015), is a key reason for loss of capability of tetraploid embryo complementation (Liu et al., 2010; Stadtfeld et al., 2010). Recently, it was reported that increased N(6)-methyladenosine ( $m^6A$ ) abundance, which is partially regulated by multiple miRNAs (Chen et al., 2015), promotes the reprogramming of mouse embryonic fibroblasts to pluripotent stem cells; conversely, reduced  $m^6A$  levels impede reprogramming (Carette et al., 2009).

### Gamete-deriving haploid embryonic stem cells

Gamete-deriving haploid ESCs technology is stemmed from nuclear transfer and has been a novel technology for mammalian genetic study and regenerative medicine (Shuai and Zhou, 2014). Since the 1970s, extensive efforts have been made to generate haploid embryos in the mouse (Tarkowski and Rossant, 1976), but it was not until 2011 that the mouse parthenogenetic haploid ESCs (phESCs) were derived from parthenogenetic haploid embryos via fluorescence-activated cell sorting of haploid cells (Elling et al., 2011; Leeb and Wutz, 2011). Moreover, mouse androgenetic haploid ESCs (ahESCs) which can function as sperm were established in 2012 (Li et al., 2012b; Yang et al., 2012). Subsequently, generations of monkey phESCs (Yang et al., 2013), and rat ahESCs and phESCs (Li et al., 2014) were reported.

As well as valuable tool for genetic screening and drug screening (Shuai and Zhou, 2014), haploid ESCs are also novel resources for regenerative medicine due to the following reasons. (i) Haploid ESCs of mouse and rat have similar pluripotency to diploid ESCs which could produce chimeric animals and contribute to the germline (Leeb et al., 2012). (ii) Both ahESCs and phESCs can generate fertile offspring (Li et al., 2012b, 2014; Wan et al., 2013). (iii) Fused ESCs from ahESCs and phESCs can generate fertile offspring through tetraploid embryo complementation (Li et al., 2015). (iv) Haploid ESCs can differentiate into haploid epiblast stem cells (Elling et al., 2011) and haploid somatic cells (unpublished data). (v) Genome-editing to repair double allele mutations is easier for haploid ESCs. (vi) Haploid ESCs may be induced into gametes by overexpressing transcription factors or adding small drug molecules.

Creatively, mouse-rat allodiploid ESCs (AdESCs) were generated using the mouse and rat haploid ESCs, and the AdESCs have similar pluripotency to mouse and rat ESCs with the ability to differentiate into all three germ layers as well as early stage germ cells while maintaining a stable allodiploid genome (Li et al., 2016a). AdESCs can serve as

a powerful tool for understanding evolution of gene regulation, which would be very useful for uncovering the nature of totipotency of mouse ESCs, and would be helpful for establishing human ESCs with higher pluripotency, especially when based on other possible AdESCs, such as mouse-monkey and even mouse-human AdESCs.

## ANIMAL MODELS: DISEASE/THERAPEUTIC MODELS AND ORGAN DEFECT MODELS

Animal disease/therapeutic models and animal models with organ defects are another useful tool for regenerative medicine. Precise genomic modifications at single nucleotide level have promoted the development of animal model construction. For a long period of time, genome editing has largely relied on traditional forward genetic screenings, which are intrinsically limited (Rubin and Spradling, 1982; Solnica-Krezel et al., 1994). With the development of artificial nuclease technology, ZFN (zinc finger nucleases), TALEN (transcription activator like effector nucleases), and CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9 (CRISPR-associated) system have boosted the development of genome-editing. Many animal models of human diseases have been established by TALEN or CRISPR/Cas9 system, including mouse (Wang et al., 2014), rat (Li et al., 2013), pig (Hai et al., 2014; Wang et al., 2015), and monkey (Liu et al., 2014; Niu et al., 2014; Wan et al., 2015).

Since blastocyst complementation was first reported by Chen, giving rise of T and B lymphocytes by injecting normal mouse ESCs in *Rag2<sup>-/-</sup>* mice which have no mature T or B cells (Chen et al., 1993), the generation of functional rat pancreas in mouse by interspecies blastocyst injection of rat ESCs reported by Kobayashi (Kobayashi et al., 2010) took an initial step toward the future regenerative medicine. Similar successes in organ generation were achieved for kidney of mouse (Usui et al., 2012) and pancreas of pig (Matsunari et al., 2013).

A great development in tissue engineering is represented by 3D bio-printing technology (Gu et al., 2015), which opens a new path for regenerative medicine and holds a great promising future. Nevertheless, it will need parallel advances in biomaterials and cell biology to achieve clinical advances.

## OUTLOOK

The 2012 Nobel Prize in physiology or medicine was awarded to Shinya Yamanaka and John Gurdon for their discovery of somatic cell reprogramming, which provides a means to obtain limitless sources of stem cells. Reprogramming marks an instrumental advance for the field of stem cells and regenerative medicine. The mechanistic aspects of reprogramming are currently under extensive investigation, and in-depth and thorough understanding of

development and reprogramming will be crucial for developing safe and effective cell therapies to realize the full potential of regenerative medicine.

In the coming decades, to generate stem cells with higher pluripotency especially from large animals and human, to establish animal disease/therapeutic models and animals with “organ niche”, and to develop new biomaterials and well-established *in vitro* differentiation system in order to generate human organs through 3D bio-printing, will be major research directions for regenerative medicine.

**Compliance and ethics** *The author(s) declare that they have no conflict of interest.*

**Acknowledgements** *This work was supported by the National Natural Science Foundation of China (31471395).*

- Andrews, P.W., Baker, D., Benvinisty, N., Miranda, B., Bruce, K., Brustle, O., Choi, M., Choi, Y.M., Crook, J.M., de Sousa, P.A., Dvorak, P., Freund, C., Firpo, M., Furue, M.K., Gokhale, P., Ha, H.Y., Han, E., Haupt, S., Healy, L., Hei, D.J., Hovatta, O., Hunt, C., Hwang, S.M., Inamdar, M.S., Isasi, R.M., Jaconi, M., Jekerle, V., Kamthorn, P., Kibbey, M.C., Knezevic, I., Knowles, B.B., Koo, S.K., Laabi, Y., Leopoldo, L., Liu, P., Lomax, G.P., Loring, J.F., Ludwig, T.E., Montgomery, K., Mummery, C., Nagy, A., Nakamura, Y., Nakatsuji, N., Oh, S., Oh, S.K., Otonkoski, T., Pera, M., Peschanski, M., Pranke, P., Rajala, K.M., Rao, M., Ruttachuk, R., Reubinoff, B., Ricco, L., Rooke, H., Sipp, D., Stacey, G.N., Suemori, H., Takahashi, T.A., Takada, K., Talib, S., Tannenbaum, S., Yuan, B.Z., Zeng, F., and Zhou, Q. (2015). Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCB). *Regen Med* 10, 1–44.
- Baguisi, A., Behboodi, E., Melican, D.T., Pollock, J.S., Destrempes, M.M., Cammuso, C., Williams, J.L., Nims, S.D., Porter, C.A., Midura, P., Palacios, M.J., Ayres, S.L., Denniston, R.S., Hayes, M.L., Ziomek, C.A., Meade, H.M., Godke, R.A., Gavin, W.G., Overstrom, E.W., and Echehard, Y. (1999). Production of goats by somatic cell nuclear transfer. *Nat Biotechnol* 17, 456–461.
- Bethhauser, J., Forsberg, E., Augenstein, M., Childs, L., Eilertsen, K., Enos, J., Forsythe, T., Golueke, P., Jurgella, G., Koppang, R., Lesmeister, T., Mallon, K., Mell, G., Misica, P., Pace, M., Pfister-Genskow, M., Strelchenko, N., Voelker, G., Watt, S., Thompson, S., and Bishop, M. (2000). Production of cloned pigs from *in vitro* systems. *Nat Biotechnol* 18, 1055–1059.
- Briggs, R., and King, T.J. (1952). Transplantation of living nuclei from blastula cells into enucleated frogs' eggs. *Proc Natl Acad Sci USA* 38, 455–463.
- Bui, H.T., Wakayama, S., Kishigami, S., Park, K.K., Kim, J.H., Thuan, N.V., and Wakayama, T. (2010). Effect of trichostatin A on chromatin remodeling, histone modifications, DNA replication, and transcriptional activity in cloned mouse embryos. *Biol Reprod* 83, 454–463.
- Carette, J.E., Guimaraes, C.P., Varadarajan, M., Park, A.S., Wuethrich, I., Godarova, A., Kotecki, M., Cochran, B.H., Spooner, E., and Ploegh, H.L. (2009). Haploid genetic screens in human cells identify host factors used by pathogens. *Science* 326, 1231–1235.
- Chen, J., Lansford, R., Stewart, V., Young, F., and Alt, F.W. (1993). RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. *Proc Natl Acad Sci USA* 90, 4528–4532.
- Chen, T., Hao, Y., Zhang, Y., Li, M., Wang, M., Han, W., Wu, Y., Lv, Y., Hao, J., Wang, L., Li, A., Yang, Y., Jin, K., Zhao, X., Li, Y., Ping, X., Lai, W., Wu, L., Jiang, G., Wang, H., Sang, L., Wang, X., Yang, Y.,

- and Zhou, Q. (2015). m(6)A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency. *Cell Stem Cell* 16, 289–301.
- Chen, X., Li, T., Li, X., Xie, Y., Guo, X., Ji, S., Niu, Y., Yu, Y., Ding, C., Yao, R., Yang, S., Ji, W., and Zhou, Q. (2009). Neural progenitors derived from monkey embryonic stem cells in a simple monoculture system. *Reprod Biomed Online* 19, 426–433.
- Chesne, P., Adenot, P.G., Viglietta, C., Baratte, M., Boulanger, L., and Renard, J.P. (2002). Cloned rabbits produced by nuclear transfer from adult somatic cells. *Nat Biotechnol* 20, 366–369.
- Cho, H.J., Lee, C.S., Kwon, Y.W., Paek, J.S., Lee, S.H., Hur, J., Lee, E.J., Roh, T.Y., Chu, I.S., Leem, S.H., Kim, Y., Kang, H.J., Park, Y.B., and Kim, H.S. (2010). Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. *Blood* 116, 386–395.
- Cibelli, J.B., Stice, S.L., Golueke, P.J., Kane, J.J., Jerry, J., Blackwell, C., Ponce de Leon, F.A., and Robl, J.M. (1998). Cloned transgenic calves produced from nonquiescent fetal fibroblasts. *Science* 280, 1256–1258.
- Dai, X., Hao, J., Hou, X., Hai, T., Fan, Y., Yu, Y., Jouneau, A., Wang, L., and Zhou, Q. (2010). Somatic nucleus reprogramming is significantly improved by m-carboxycinnamic acid bishydroxamide, a histone deacetylase inhibitor. *J Biol Chem* 285, 31002–31010.
- Dai, X., Hao, J., and Zhou, Q. (2009). A modified culture method significantly improves the development of mouse somatic cell nuclear transfer embryos. *Reproduction* 138, 301–308.
- Das, P.P., Hendrix, D.A., Apostolou, E., Buchner, A.H., Canver, M.C., Beyaz, S., Ljuboja, D., Kuintzle, R., Kim, W., Karnik, R., Shao, Z., Xie, H., Xu, J., De Los Angeles, A., Zhang, Y., Choe, J., Jun, D.L., Shen, X., Gregory, R.I., Daley, G.Q., Meissner, A., Kellis, M., Hochlinger, K., Kim, J., and Orkin, S.H. (2015). PRC2 is required to maintain expression of the maternal *Gtl2-Rian-Mirg* locus by preventing *de novo* DNA methylation in mouse embryonic stem cells. *Cell Rep* 12, 1456–1470.
- Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* 51, 987–1000.
- Dean, W., Santos, F., Stojkovic, M., Zakhartchenko, V., Walter, J., Wolf, E., and Reik, W. (2001). Conservation of methylation reprogramming in mammalian development: aberrant reprogramming in cloned embryos. *Proc Natl Acad Sci USA* 98, 13734–13738.
- Ding, C., Huang, S., Qi, Q., Fu, R., Zhu, W., Cai, B., Hong, P., Liu, Z., Gu, T., Zeng, Y., Wang, J., Xu, Y., Zhao, X., Zhou, Q., and Zhou, C. (2015). Derivation of a homozygous human androgenetic embryonic stem cell line. *Stem Cells Dev* 24, 2307–2316.
- Elling, U., Taubenschmid, J., Wirnsberger, G., O'Malley, R., Demers, S.P., Vanhaelen, Q., Shukalyuk, A.I., Schmauss, G., Schramek, D., Schnuetgen, F., von Melchner, H., Ecker, J.R., Stanford, W.L., Zuber, J., Stark, A., and Penninger, J.M. (2011). Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. *Cell Stem Cell* 9, 563–574.
- Esteban, M.A., Wang, T., Qin, B., Yang, J., Qin, D., Cai, J., Li, W., Weng, Z., Chen, J., Ni, S., Chen, K., Li, Y., Liu, X., Xu, J., Zhang, S., Li, F., He, W., Labuda, K., Song, Y., Peterbauer, A., Wolbank, S., Redl, H., Zhong, M., Cai, D., Zeng, L., and Pei, D. (2010). Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. *Cell Stem Cell* 6, 71–79.
- Evans, M.J., and Kaufman, M.H. (1981). Establishment in culture of pluripotential cells from mouse embryos. *Nature* 292, 154–156.
- Galli, C., Lagutina, I., Crotti, G., Colleoni, S., Turini, P., Ponderato, N., Duchi, R., and Lazzari, G. (2003). Pregnancy: a cloned horse born to its dam twin. *Nature* 424, 635.
- Germanà, M.A. (2011). Gametic embryogenesis and haploid technology as valuable support to plant breeding. *Plant Cell Rep* 30, 839–857.
- Gu, Q., Hao, J., Hai, T., Wang, J., Jia, Y., Kong, Q., Wang, J., Feng, C., Xue, B., Xie, B., Liu, S., Li, J., He, Y., Sun, J., Liu, L., Wang, L., Liu, Z., and Zhou, Q. (2014). Efficient generation of mouse ESCs-like pig induced pluripotent stem cells. *Protein Cell* 5, 338–342.
- Gu, Q., Hao, J., Lu, Y., Wang, L., Wallace, G.G., and Zhou, Q. (2015). Three-dimensional bio-printing. *Sci China Life Sci* 58, 411–419.
- Gu, Q., Hao, J., Zhao, X., Li, W., Liu, L., Wang, L., Liu, Z., and Zhou, Q. (2012). Rapid conversion of human ESCs into mouse ESC-like pluripotent state by optimizing culture conditions. *Protein Cell* 3, 71–79.
- Gurdon, J.B., Elsdale, T.R., and Fischberg, M. (1958). Sexually mature individuals of *Xenopus laevis* from the transplantation of single somatic nuclei. *Nature* 182, 64–65.
- Hai, T., Hao, J., Wang, L., Jouneau, A., and Zhou, Q. (2011). Pluripotency maintenance in mouse somatic cell nuclear transfer embryos and its improvement by treatment with the histone deacetylase inhibitor TSA. *Cell Reprogram* 13, 47–56.
- Hai, T., Teng, F., Guo, R., Li, W., and Zhou, Q. (2014). One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. *Cell Res* 24, 372–375.
- Hanna, J., Cheng, A.W., Saha, K., Kim, J., Lengner, C.J., Soldner, F., Cassady, J.P., Muffat, J., Carey, B.W., and Jaenisch, R. (2010). Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. *Proc Natl Acad Sci USA* 107, 9222–9227.
- Hao, J., Zhu, W., Sheng, C., Yu, Y., and Zhou, Q. (2009). Human parthenogenetic embryonic stem cells: one potential resource for cell therapy. *Sci China C Life Sci* 52, 599–602.
- Hemberger, M., Dean, W., Reik, W., 2009. Epigenetic dynamics of stem cells and cell lineage commitment: digging Waddington's canal. *Nat Rev Mol Cell Biol* 10, 526–537.
- Herson, P.S., Virk, M., Rustay, N.R., Bond, C.T., Crabbe, J.C., Adelman, J.P., and Maylie, J. (2003). A mouse model of episodic ataxia type-1. *Nat Neurosci* 6, 378–383.
- Hou, P., Li, Y., Zhang, X., Liu, C., Guan, J., Li, H., Zhao, T., Ye, J., Yang, W., Liu, K., Ge, J., Xu, J., Zhang, Q., Zhao, Y., and Deng, H. (2013). Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. *Science* 341, 651–654.
- Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.E., and Melton, D.A. (2008). Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. *Nat Biotechnol* 26, 795–797.
- Hwang, W.S., Ryu, Y.J., Park, J.H., Park, E.S., Lee, E.G., Koo, J.M., Jeon, H.Y., Lee, B.C., Kang, S.K., Kim, S.J., Ahn, C., Hwang, J.H., Park, K.Y., Cibelli, J.B., and Moon, S.Y. (2004). Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst. *Science* 303, 1669–1674.
- Iannaccone, P.M., Taborn, G.U., Garton, R.L., Caplice, M.D., and Brenin, D.R. (1994). Pluripotent embryonic stem cells from the rat are capable of producing chimeras. *Dev Biol* 163, 288–292.
- International Stem Cell Banking, I. (2009). Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes. *Stem Cell Rev* 5, 301–314.
- Kang, Y.K., Koo, D.B., Park, J.S., Choi, Y.H., Chung, A.S., Lee, K.K., and Han, Y.M. (2001). Aberrant methylation of donor genome in cloned bovine embryos. *Nat Genet* 28, 173–177.
- Kato, Y., Tani, T., Sotomaru, Y., Kurokawa, K., Kato, J., Doguchi, H., Yasue, H., and Tsunoda, Y. (1998). Eight calves cloned from somatic cells of a single adult. *Science* 282, 2095–2098.
- Kim, D., Kim, C.H., Moon, J.I., Chung, Y.G., Chang, M.Y., Han, B.S., Ko, S., Yang, E., Cha, K.Y., Lanza, R., and Kim, K.S. (2009). Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. *Cell Stem Cell* 4, 472–476.
- Kishigami, S., Mizutani, E., Ohta, H., Hikichi, T., Thuan, N.V., Wakayama, S., Bui, H.T., and Wakayama, T. (2006). Significant improvement of mouse cloning technique by treatment with trichostatin A after somatic nuclear transfer. *Biochem Biophys Res Commun* 340, 183–189.
- Kobayashi, T., Yamaguchi, T., Hamanaka, S., Kato-Itoh, M., Yamazaki, Y., Ibata, M., Sato, H., Lee, Y.S., Usui, J., Knisely, A.S., Hirabayashi, M., and Nakauchi, H. (2010). Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. *Cell* 142,

- 787–799.
- Laiosa, C.V., Stadtfeld, M., Xie, H., de Andres-Aguayo, L., and Graf, T. (2006). Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/EBP alpha and PU.1 transcription factors. *Immunity* 25, 731–744.
- Lee, B.C., Kim, M.K., Jang, G., Oh, H.J., Yuda, F., Kim, H.J., Hossein, M.S., Kim, J.J., Kang, S.K., Schatten, G., and Hwang, W.S. (2005). Dogs cloned from adult somatic cells. *Nature* 436, 641.
- Lee, J., Sayed, N., Hunter, A., Au, K.F., Wong, W.H., Mocarski, E.S., Pera, R.R., Yakubov, E., and Cooke, J.P. (2012). Activation of innate immunity is required for efficient nuclear reprogramming. *Cell* 151, 547–558.
- Leeb, M., Walker, R., Mansfield, B., Nichols, J., Smith, A., and Wutz, A. (2012). Germline potential of parthenogenetic haploid mouse embryonic stem cells. *Development* 139, 3301–3305.
- Leeb, M., and Wutz, A. (2011). Derivation of haploid embryonic stem cells from mouse embryos. *Nature* 479, U131–U164.
- Li, T., Wang, S., Xie, Y., Lu, Y., Zhang, X., Wang, L., Yang, S., Wolf, D., Zhou, Q., and Ji, W. (2005a). Homologous feeder cells support undifferentiated growth and pluripotency in monkey embryonic stem cells. *Stem Cells* 23, 1192–1199.
- Li, T., Zhao, X., Teng, F., Li, X., Jiang, M., Li, W., Wang, X., Wang, J., Liu, L., Liu, Z., Wang, L., and Zhou, Q. (2012a). Derivation of germline competent rat embryonic stem cells from DA rats. *J Genet Genomics* 39, 603–606.
- Li, T., Zheng, J., Xie, Y., Wang, S., Zhang, X., Li, J., Jin, L., Ma, Y., Wolf, D.P., Zhou, Q., and Ji, W. (2005). Transplantable neural progenitor populations derived from rhesus monkey embryonic stem cells. *Stem Cells* 23, 1295–1303.
- Li, W., Li, X., Li, T., Jiang, M., Wan, H., Luo, G., Feng, C., Cui, X., Teng, F., Yuan, Y., Zhou, Q., Gu, Q., Shuai, L., Sha, J., Xiao, Y., Wang, L., Liu, Z., Wang, X., Zhao, X., and Zhou, Q. (2014). Genetic modification and screening in rat using haploid embryonic stem cells. *Cell Stem Cell* 14, 404–414.
- Li, W., Shuai, L., Wan, H., Dong, M., Wang, M., Sang, L., Feng, C., Luo, G., Li, T., Li, X., Wang, L., Zheng, Q., Sheng, C., Wu, H., Liu, Z., Liu, L., Wang, L., Wang, X., Zhao, X., and Zhou, Q. (2012b). Androgenetic haploid embryonic stem cells produce live transgenic mice. *Nature* 490, 407–411.
- Li, W., Teng, F., Li, T., and Zhou, Q. (2013). Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. *Nat Biotechnol* 31, 684–686.
- Li, W., Zhao, X., Wan, H., Zhang, Y., Liu, L., Lv, Z., Wang, X., Wang, L., and Zhou, Q. (2011). iPSCs generated without c-Myc have active Dlk1-Dio3 region and are capable of producing full-term mice through tetraploid complementation. *Cell Res* 21, 550–553.
- Li, X., Cui, X., Wang, J., Wang, Y., Li, Y., Wang, L., Wan, H., Li, T., Feng, G., Shuai, L., Li, Z., Gu, Q., Hao, J., Wang, L., Zhao, X., Liu, Z., Wang, X., Li, W., and Zhou, Q. (2016a). Generation and application of mouse-rat allodiploid embryonic stem cells. *Cell* 164, 279–292.
- Li, X., Wang, J., Wang, L., Wan, H., Li, Y., Li, T., Wang, Y., Shuai, L., Mao, Y., Cui, X., Wang, L., Liu, Z., Li, W., and Zhou, Q. (2015). Co-participation of paternal and maternal genomes before the blastocyst stage is not required for full-term development of mouse embryos. *J Mol Cell Biol* 7, 486–488.
- Li, Z., Sun, X., Chen, J., Liu, X., Wisely, S.M., Zhou, Q., Renard, J.P., Leno, G.H., and Engelhardt, J.F. (2006). Cloned ferrets produced by somatic cell nuclear transfer. *Dev Biol* 293, 439–448.
- Liu, H., Chen, Y., Niu, Y., Zhang, K., Kang, Y., Ge, W., Liu, X., Zhao, E., Wang, C., Lin, S., Jing, B., Si, C., Lin, Q., Chen, X., Lin, H., Pu, X., Wang, Y., Qin, B., Wang, F., Wang, H., Si, W., Zhou, J., Tan, T., Li, T., Ji, S., Xue, Z., Luo, Y., Cheng, L., Zhou, Q., Li, S., Sun, Y., and Ji, W. (2014). TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. *Cell Stem Cell* 14, 323–328.
- Liu, L., Luo, G., Yang, W., Zhao, X., Zheng, Q., Lv, Z., Li, W., Wu, H., Wang, L., Wang, X., and Zhou, Q. (2010). Activation of the imprinted Dlk1-Dio3 region correlates with pluripotency levels of mouse stem cells. *J Biol Chem* 285, 19483–19490.
- Ma, M., Guo, X., Wang, F., Zhao, C., Liu, Z., Shi, Z., Wang, Y., Zhang, P., Zhang, K., Wang, N., Lin, M., Zhou, Z., Liu, J., Li, Q., Wang, L., Huo, R., Sha, J., and Zhou, Q. (2008). Protein expression profile of the mouse metaphase-II oocyte. *J Proteome Res* 7, 4821–4830.
- Martin, G.R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci USA* 78, 7634–7638.
- Matsunari, H., Nagashima, H., Watanabe, M., Umeyama, K., Nakano, K., Nagaya, M., Kobayashi, T., Yamaguchi, T., Sumazaki, R., Herzenberg, L.A., and Nakauchi, H. (2013). Blastocyst complementation generates exogenic pancreas *in vivo* in apancreatic cloned pigs. *Proc Natl Acad Sci USA* 110, 4557–4562.
- Mikkelsen, T.S., Hanna, J., Zhang, X., Ku, M., Wernig, M., Schorderet, P., Bernstein, B.E., Jaenisch, R., Lander, E.S., and Meissner, A. (2008). Dissecting direct reprogramming through integrative genomic analysis. *Nature* 454, 49–55.
- Niu, Y., Shen, B., Cui, Y., Chen, Y., Wang, J., Wang, L., Kang, Y., Zhao, X., Si, W., Li, W., Xiang, A., Zhou, J., Guo, X., Bi, Y., Si, C., Hu, B., Dong, G., Wang, H., Zhou, Z., Li, T., Tan, T., Pu, X., Wang, F., Ji, S., Zhou, Q., Huang, X., Ji, W., and Sha, J. (2014). Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. *Cell* 156, 836–843.
- Ohgane, J., Wakayama, T., Kogo, Y., Senda, S., Hattori, N., Tanaka, S., Yanagimachi, R., and Shiota, K. (2001). DNA methylation variation in cloned mice. *Genesis* 30, 45–50.
- Ohnuki, M., Tanabe, K., Sutou, K., Teramoto, I., Sawamura, Y., Narita, M., Nakamura, M., Tokunaga, Y., Nakamura, M., Watanabe, A., Yamanaoka, S., and Takahashi, K. (2014). Dynamic regulation of human endogenous retroviruses mediates factor-induced reprogramming and differentiation potential. *Proc Natl Acad Sci USA* 111, 12426–12431.
- Onishi, A., Iwamoto, M., Akita, T., Mikawa, S., Takeda, K., Awata, T., Hanada, H., and Perry, A.C. (2000). Pig cloning by microinjection of fetal fibroblast nuclei. *Science* 289, 1188–1190.
- Polejaeva, I.A., Chen, S.H., Vaught, T.D., Page, R.L., Mullins, J., Ball, S., Dai, Y., Boone, J., Walker, S., Ayares, D.L., Colman, A., and Campbell, K.H. (2000). Cloned pigs produced by nuclear transfer from adult somatic cells. *Nature* 407, 86–90.
- Rashid, T., Kobayashi, T., and Nakauchi, H. (2014). Revisiting the flight of icarus: making human organs from PSCs with large animal chimeras. *Cell Stem Cell* 15, 406–409.
- Riaz, A., Javeed, A., and Zhou, Q. (2011). Therapeutic cloning by xenotransplanted oocytes, supplemented with species specific reprogramming factors. *Med Hypotheses* 76, 527–529.
- Rubin, G.M., and Spradling, A.C. (1982). Genetic transformation of *Drosophila* with transposable element vectors. *Science* 218, 348–353.
- Shen, C.N., Slack, J.M., and Tosh, D. (2000). Molecular basis of transdifferentiation of pancreas to liver. *Nat Cell Biol* 2, 879–887.
- Sheng, C., Zheng, Q., Wu, J., Xu, Z., Sang, L., Wang, L., Guo, C., Zhu, W., Tong, M., Liu, L., Li, W., Liu, Z., Zhao, X., Wang, L., Chen, Z., and Zhou, Q. (2012a). Generation of dopaminergic neurons directly from mouse fibroblasts and fibroblast-derived neural progenitors. *Cell Res* 22, 769–772.
- Sheng, C., Zheng, Q., Wu, J., Xu, Z., Wang, L., Li, W., Zhang, H., Zhao, X., Liu, L., Wang, Z., Guo, C., Wu, H., Liu, Z., Wang, L., He, S., Wang, X., Chen, Z., and Zhou, Q. (2012b). Direct reprogramming of Sertoli cells into multipotent neural stem cells by defined factors. *Cell Res* 22, 208–218.
- Shi, Y., Do, J.T., Despons, C., Hahm, H.S., Scholer, H.R., and Ding, S. (2008). A combined chemical and genetic approach for the generation of induced pluripotent stem cells. *Cell Stem Cell* 2, 525–528.
- Shin, T., Kraemer, D., Pryor, J., Liu, L., Rugila, J., Howe, L., Buck, S., Murphy, K., Lyons, L., and Westhusin, M. (2002). A cat cloned by nuclear transplantation. *Nature* 415, 859.
- Shinagawa, T., Takagi, T., Tsukamoto, D., Tomaru, C., Huynh, L.M.,

- Sivaraman, P., Kumarevel, T., Inoue, K., Nakato, R., Katou, Y., Sado, T., Takahashi, S., Ogura, A., Shirahige, K., and Ishii, S. (2014). Histone variants enriched in oocytes enhance reprogramming to induced pluripotent stem cells. *Cell Stem Cell* 14, 217–227.
- Shuai, L., Wang, Y., Dong, M., Wang, X., Sang, L., Wang, M., Wan, H., Luo, G., Gu, T., Yuan, Y., Feng, C., Teng, F., Li, W., Liu, X., Li, T., Wang, L., Wang, X., Zhao, X., and Zhou, Q. (2015). Durable pluripotency and haploidy in epiblast stem cells derived from haploid embryonic stem cells *in vitro*. *J Mol Cell Biol* 7, 326–337.
- Shuai, L., and Zhou, Q. (2014). Haploid embryonic stem cells serve as a new tool for mammalian genetic study. *Stem Cell Res Ther* 5, 20.
- Solnica-Krezel, L., Schier, A.F., and Driever, W. (1994). Efficient recovery of ENU-induced mutations from the zebrafish germline. *Genetics* 136, 1401–1420.
- Song, Y., Hai, T., Wang, Y., Guo, R., Li, W., Wang, L., and Zhou, Q. (2014). Epigenetic reprogramming, gene expression and *in vitro* development of porcine SCNT embryos are significantly improved by a histone deacetylase inhibitor—*m*-carboxycinnamic acid bishydroxamide (CBHA). *Protein Cell* 5, 382–393.
- Stadtfeld, M., Apostolou, E., Akutsu, H., Fukuda, A., Follett, P., Natesan, S., Kono, T., Shioda, T., and Hochedlinger, K. (2010). Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. *Nature* 465, 175–181.
- Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126, 663–676.
- Tarkowski, A.K., and Rossant, J. (1976). Haploid mouse blastocysts developed from bisected zygotes. *Nature* 259, 663–665.
- Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., and Jones, J.M. (1998). Embryonic stem cell lines derived from human blastocysts. *Science* 282, 1145–1147.
- Thomson, J.A., Kalishman, J., Golos, T.G., Durning, M., Harris, C.P., and Hearn, J.P. (1996). Pluripotent cell lines derived from common marmoset (*Callithrix jacchus*) blastocysts. *Biol Reprod* 55, 254–259.
- Tong, M., Lv, Z., Liu, L., Zhu, H., Zheng, Q., Zhao, X., Li, W., Wu, Y., Zhang, H., Wu, H., Li, Z., Zeng, F., Wang, L., Wang, X., Sha, J., and Zhou, Q. (2011). Mice generated from tetraploid complementation competent iPS cells show similar developmental features as those from ES cells but are prone to tumorigenesis. *Cell Res* 21, 1634–1637.
- Usui, J., Kobayashi, T., Yamaguchi, T., Knisely, A.S., Nishinakamura, R., and Nakauchi, H. (2012). Generation of kidney from pluripotent stem cells via blastocyst complementation. *Am J Pathol* 180, 2417–2426.
- Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Sudhof, T.C., and Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. *Nature* 463, 1035–1041.
- Wakayama, T., Perry, A.C., Zuccotti, M., Johnson, K.R., and Yanagimachi, R. (1998). Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. *Nature* 394, 369–374.
- Wan, H., Feng, C., Teng, F., Yang, S., Hu, B., Niu, Y., Xiang, A., Fang, W., Ji, W., Li, W., Zhao, X., and Zhou, Q. (2015). One-step generation of p53 gene biallelic mutant cynomolgus monkey via the CRISPR/Cas system. *Cell Res* 25, 258–261.
- Wan, H., He, Z., Dong, M., Gu, T., Luo, G., Teng, F., Xia, B., Li, W., Feng, C., Li, X., Li, T., Shuai, L., Fu, R., Wang, L., Wang, X., Zhao, X., and Zhou, Q. (2013). Parthenogenetic haploid embryonic stem cells produce fertile mice. *Cell Res* 23, 1330–1333.
- Wang, S., Shen, Y., Yuan, X., Chen, K., Guo, X., Chen, Y., Niu, Y., Li, J., Xu, R., Yan, X., Zhou, Q., and Ji, W. (2008). Dissecting signaling pathways that govern self-renewal of rabbit embryonic stem cells. *J Biol Chem* 283, 35929–35940.
- Wang, S., Tang, X., Niu, Y., Chen, H., Li, B., Li, T., Zhang, X., Hu, Z., Zhou, Q., and Ji, W. (2007). Generation and characterization of rabbit embryonic stem cells. *Stem Cells* 25, 481–489.
- Wang, X., Yuan, Y., Zhou, Q., Wan, H., Wang, M., Zhou, Q., Zhao, X., and Sha, J. (2014). RNA guided genome editing in mouse germ-line stem cells. *J Genet Genomics* 41, 409–411.
- Wang, X., Zhou, J., Cao, C., Huang, J., Hai, T., Wang, Y., Zheng, Q., Zhang, H., Qin, G., Miao, X., Wang, H., Cao, S., Zhou, Q., and Zhao, J. (2015). Efficient CRISPR/Cas9-mediated biallelic gene disruption and site-specific knockin after rapid selection of highly active sgRNAs in pigs. *Sci Rep* 5, 13348.
- Wang, Y., Hai, T., Liu, Z., Zhou, S., Lv, Z., Ding, C., Liu, L., Niu, Y., Zhao, X., Tong, M., Wang, L., Jouneau, A., Zhang, X., Ji, W., and Zhou, Q. (2010). HSPC117 deficiency in cloned embryos causes placental abnormality and fetal death. *Biochem Biophys Res Commun* 397, 407–412.
- Wani, N.A., Wernery, U., Hassan, F.A., Wernery, R., and Skidmore, J.A. (2010). Production of the first cloned camel by somatic cell nuclear transfer. *Biol Reprod* 82, 373–379.
- Wei, L., and Cao, X. (2016). The effect of transposable elements on phenotypic variation: insights from plants to humans. *Sci China Life Sci* 59, 24–37.
- Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J., and Campbell, K.H. (1997). Viable offspring derived from fetal and adult mammalian cells. *Nature* 385, 810–813.
- Woods, G.L., White, K.L., Vanderwall, D.K., Li, G.P., Aston, K.I., Bunch, T.D., Meerdo, L.N., and Pate, B.J. (2003). A mule cloned from fetal cells by nuclear transfer. *Science* 301, 1063.
- Xie, H., Ye, M., Feng, R., and Graf, T. (2004). Stepwise reprogramming of B cells into macrophages. *Cell* 117, 663–676.
- Yamazaki, Y., Fujita, T.C., Low, E.W., Alarcon, V.B., Yanagimachi, R., and Marikawa, Y. (2006). Gradual DNA demethylation of the Oct4 promoter in cloned mouse embryos. *Mol Reprod Dev* 73, 180–188.
- Yang, H., Liu, Z., Ma, Y., Zhong, C., Yin, Q., Zhou, C., Shi, L., Cai, Y., Zhao, H., Wang, H., Tang, F., Wang, Y., Zhang, C., Liu, X., Lai, D., Jin, Y., Sun, Q., and Li, J. (2013). Generation of haploid embryonic stem cells from *Macaca fascicularis* monkey parthenotes. *Cell Res* 23, 1187–1200.
- Yang, H., Shi, L., Wang, B., Liang, D., Zhong, C., Liu, W., Nie, Y., Liu, J., Zhao, J., Gao, X., Li, D., Xu, G., and Li, J. (2012). Generation of genetically modified mice by oocyte injection of androgenetic haploid embryonic stem cells. *Cell* 149, 605–617.
- Yu, Y., Mai, Q., Chen, X., Wang, L., Gao, L., Zhou, C., and Zhou, Q. (2009). Assessment of the developmental competence of human somatic cell nuclear transfer embryos by oocyte morphology classification. *Hum Reprod* 24, 649–657.
- Yuan, X., Wan, H., Zhao, X., Zhu, S., Zhou, Q., and Ding, S. (2011). Brief report: combined chemical treatment enables Oct4-induced reprogramming from mouse embryonic fibroblasts. *Stem Cells* 29, 549–553.
- Yuan, Y., Zhou, Q., Wan, H., Shen, B., Wang, X., Wang, M., Feng, C., Xie, M., Gu, T., Zhou, T., Fu, R., Huang, X., Zhou, Q., Sha, J., and Zhao, X. (2015). Generation of fertile offspring from *Kit<sup>fl</sup>/Kit<sup>wv</sup>* mice through differentiation of gene corrected nuclear transfer embryonic stem cells. *Cell Res* 25, 851–863.
- Zhao, X., Li, W., Lv, Z., Liu, L., Tong, M., Hai, T., Hao, J., Guo, C., Ma, Q., Wang, L., Zeng, F., and Zhou, Q. (2009). iPS cells produce viable mice through tetraploid complementation. *Nature* 461, 86–90.
- Zhao, X., Li, W., Lv, Z., Liu, L., Tong, M., Hai, T., Hao, J., Guo, C., Wang, X., Wang, L., Zeng, F., and Zhou, Q. (2010a). Efficient and rapid generation of induced pluripotent stem cells using an alternative culture medium. *Cell Res* 20, 383–386.
- Zhao, X., Li, W., Lv, Z., Liu, L., Tong, M., Hai, T., Hao, J., Wang, X., Wang, L., Zeng, F., and Zhou, Q. (2010b). Viable fertile mice generated from fully pluripotent iPS cells derived from adult somatic cells. *Stem Cell Rev* 6, 390–397.
- Zhao, X., Lv, Z., Li, W., Zeng, F., and Zhou, Q. (2010c). Production of mice using iPS cells and tetraploid complementation. *Nat Protoc* 5, 963–971.
- Zhao, Y., Zhao, T., Guan, J., Zhang, X., Fu, Y., Ye, J., Zhu, J., Meng, G., Ge, J., Yang, S., Cheng, L., Du, Y., Zhao, C., Wang, T., Su, L., Yang, W., and Deng, H. (2015). A XEN-like state bridges somatic cells to pluripotency during chemical reprogramming. *Cell* 163, 1678–1691.

- Zhou, H., Wu, S., Joo, J.Y., Zhu, S., Han, D.W., Lin, T., Trauger, S., Bien, G., Yao, S., Zhu, Y., Siuzdak, G., Scholer, H.R., Duan, L., and Ding, S. (2009). Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell* 4, 381–384.
- Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., and Melton, D.A. (2008). *In vivo* reprogramming of adult pancreatic exocrine cells to beta-cells. *Nature* 455, 627–632.
- Zhou, Q., Renard, J.P., Le Friec, G., Brochard, V., Beaujean, N., Cherifi, Y., Fraichard, A., and Cozzi, J. (2003). Generation of fertile cloned rats by regulating oocyte activation. *Science* 302, 1179.
- Zhou, Q., Wang, M., Yuan, Y., Wang, X., Fu, R., Wan, H., Xie, M., Liu, M., Guo, X., Zheng, Y., Feng, G., Shi, Q., Zhao, X., Sha, J., and Zhou, Q. (2016). Complete meiosis from embryonic stem cell-derived germ cells *in vitro*. *Cell Stem Cell* 18, 330–340.
- Zhou, Q., Yang, S., Ding, C., He, X., Xie, Y., Hildebrandt, T.B., Mitalipov, S.M., Tang, X., Wolf, D.P., and Ji, W. (2006). A comparative approach to somatic cell nuclear transfer in the rhesus monkey. *Hum Reprod* 21, 2564–2571.
- Zhou, S., Ding, C., Zhao, X., Wang, E., Dai, X., Liu, L., Li, W., Liu, Z., Wan, H., Feng, C., Hai, T., Wang, L., and Zhou, Q. (2010). Successful generation of cloned mice using nuclear transfer from induced pluripotent stem cells. *Cell Res* 20, 850–853.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.